This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. 
2) Laboratory Methods
Formalin-fixed, paraffin-embedded tumor tissue was retrieved, anonymized and encoded with the patient's trial number at the treating hospital, then sent to the research laboratory. Here, all staff were blind to the patients' treatment allocation and clinical outcomes. The laboratory processing and storage of samples was under Ethical approval, and the laboratory adheres where possible to GCLP guidelines and participates annually in the UK National External Quality Assessment Service (NEQAS) scheme.
Areas containing the highest density of tumour cells were identified on a hematoxylin and eosin stained section. Six to nine 5 µm sections were used per extraction, depending upon the tumour area per slide. The sections were macrodissected with a scalpel blade, to ensure that only the tumour-rich areas were used. DNA was extracted using the Qiagen QiaAmp Micro Kit (Qiagen, Crawley, UK) following the manufacturer's instructions. The final DNA was eluted into 25 microlitres of laboratory-grade water and the concentration determined using a Nanodrop ND-1000 spectrophotometer (Labtech International, Uckfield, East Sussex, UK). The DNA was stored at 4 o C until required.
Primers for PCR amplification and Pyrosequencing analysis were designed using proprietary Pyrosequencing assay design software version 2.0. 
4) Sensitivity analyses a) All-mut status definition sensitivity analysis
In the main analysis, patients with an incomplete set of genetic data are included in the "All-wt" group provided their status is wt at every codon for which data is available. In Table 4 (Webappendix), these data are shown in the top row, and for comparison, in the second row, the data for patients with a full set of data confirming wildtype status at all 12 loci under investigation (n=237). Data are given for each efficacy endpoint for this patient group and the tests for interaction with "any-mut" status. In the main analysis, mutations at PIK3CA exon 9 or 20 are grouped along with mutations in the RAS-RAF-MEK pathway for inclusion in the "Any-mut" group, shown here in the second row (n=137) of Table 5 (Webappendix). However the role of PIK3CA in EGFR signalling is less direct. The sensitivity analysis presented here shows treatment impact when the 26 patients with only a PIK3CA mutation are not included (third row, n=111). Also shown are the treatment effects in patients with only a PIK3CA mutation, although numbers here are extremely small, and the confidence intervals correspondingly wide. 
